Skip to main content

Table 3 Persistence on index treatment among Medicaid beneficiaries newly prescribed ART

From: Real-world adherence and persistence for newly-prescribed HIV treatment: single versus multiple tablet regimen comparison among US medicaid beneficiaries

Persistence assessmentNumber of days on therapyPatients with 12-month persistence among those with 12 months follow-upPatients with discontinuation of first-line therapyb
MedianN (%)N (%)
All Regimens (STR + MTR) [N = 2409]156.0410 (43.2%)953 (39.6%)
STRs [N = 1782]166.0313 (45.0%)647 (36.31%)
 EVG/COBI/FTC/TAF [N = 274]145.08 (100.0%)32 (11.7%)
 EVG/COBI/FTC/TDF [N = 475]198.0111 (43.4%)224 (47.2%)
 ABC/3TC/DTG [N = 522]180.0106 (53.3%)152 (21.6%)
 RPV/FTC/TAF [N = 27]131.0N/Aa0 (0.0%)
 RPV/FTC/TDF [N = 196]158.537 (38.9%)92 (46.9%)
 EFV/FTC/TDF [N = 288]140.051 (37.2%)147 (51.0%)
MTRs [N = 627]128.097 (38.0%)306 (48.8%)
 ABC/3TC + DRV/r [N = 12]146.02 (50.0%)3 (25.0%)
 FTC/TDF + DTG [N = 205]151.032 (47.8%)92 (44.9%)
 FTC/TAF + DTG [N = 31]79.0N/Aa0 (0.0%)
 FTC/TDF + DRV/r [N = 184]119.034 (33.3%)110 (59.8%)
 FTC/TDF + DRV/c [N = 50]144.04 (30.8%)25 (50.0%)
 FTC/TDF + ATV/r [N = 121]120.025 (37.3%)71 (58.7%)
  1. MTRs including ABC/3TC + DRV/c, FTC/TAF/r/c, FTC/TDF + ATV/c, and FTC/TAF + ATV/r/c were not examined due to the limited sample size
  2. 3TC lamivudine, ABC abacavir, ATV atazanavir, ATV/c atazanavir boosted with cobicistat, ATV/r atazanavir boosted with ritonavir, COBI cobicistat, DRV darunavir, DRV/r darunavir boosted with ritonavir, DRV/c darunavir boosted with cobicistat, DTG dolutegravir, EFV efavirenz, EVG elvitegravir, FTC emtricitabine, MTR multi-tablet regimen, RPV rilpivirine, STR single tablet regimen, TAF tenofovir alafenamide fumarate, TDF tenofovir disoproxil fumarate
  3. aEVG/COBI/FTC/TAF was approved by the FDA in November 2015, RPV/FTC/TAF was approved March 2016, and FTC/TAF was approved April 2016, thus limiting the number of patients with 12 months of follow-up
  4. bAge groups (18–34 years, 35–49 years, 50–64 years and ≥ 65 years), gender (female and male), race (White, Black, Hispanic and other), insurance type (HMO and COMP), baseline clinical comorbidities (central nervous system toxicity, gastrointestinal symptoms, mental disorders, AIDS-defining condition, substance abuse, jaundice, dyslipidemia, diabetes, chronic kidney disease, cardiovascular disease and myocardial infarction), pre index medication use (antihypertensive, antidiabetics, anticoagulants, antiarrhythmic drugs, lipid-lowering therapy, antibiotics and respiratory drugs), number of unique medications on index date other than antiretroviral therapy (ART), and Deyo-modified CCI score